STRATA Skin Sciences, Inc. SSKN
At closeNov 2, 2026, 4:00 PM EST
After hours · Nov 2, 4:00 PM ET
- YTD
- -99.99%
- 1 year
- -99.99%
- Market cap
- 588
- Revenue (ttm)
- 32.73M
- Profit margin
- -25.40%
- EPS (ttm)
- -135.00
- Shares out
- 4.17M
- Forward P/E
- -2.53
- YTD return
- -99.99%
- 1-year return
- -99.99%
- Volume
- 4.88K
- Avg volume
- 3.73K
- Open
- 0.134
- Previous close
- 0.0001
- Day's range
- 0.121 – 0.134
- 52-week range
- 0.0001 – 1.75
- Beta
- 1.32
- Analysts
- Strong Buy
- Price target
- 16.00 (+15999900.0%)
2Y -3.0299 (-100.00%)
Key statistics
- Enterprise value
- 23.96M
- PEG ratio
- 0.00
- Price / sales
- 0.37
- Price / book
- 0.80
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 2.20%
- Free cash flow
- 1.44M
- Total cash
- 5.48M
- Total debt
- 16.51M
- Return on equity
- -62.97%
- Short % of float
- 0.22%
- 50-day average
- 3.04
- 200-day average
- 3.51
Analyst view
Consensus: strong buy
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.40.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | 0.00 | -0.53 | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | -0.03 | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | -1.00 | — | — |
| Mar 27, 2024 | Dec 1, 2023 | 0.00 | -0.40 | — | — |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | -0.30 | — | — |
| Aug 9, 2023 | Jun 1, 2023 | 0.00 | -0.90 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 16, 2023 | CG Capital | reit | — | Outperform |
| Nov 3, 2020 | HC Wainwright & Co. | up | Neutral | Buy |
| Mar 17, 2020 | HC Wainwright & Co. | down | Buy | Neutral |
| Dec 9, 2019 | Ladenburg Thalmann | init | — | Buy |
| Nov 21, 2019 | Oppenheimer | init | — | Outperform |
| Dec 10, 2018 | Northland Capital Markets | init | — | Outperform |
About STRATA Skin Sciences, Inc.
STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. The company products include XTRAC and Pharos excimer lasers, and VTRAC lamp systems for the treatment systems that are used for the treatment of psoriasis, vitiligo, and other skin conditions. It also offers TheraClear Acne Therapy System for the treatment of mild to moderate inflammatory, comedonal, and pustular acne. The company was formerly known as MELA Sciences, Inc and changed its name to STRATA Skin Sciences, Inc. in January 2016. STRATA Skin Sciences, Inc. was incorporated in 1989 and is based in Horsham, Pennsylvania.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- strataskinsciences.com
News
STRATA Skin Sciences Appoints Medical Device Commercial Leader Erica Jordan as Chief Executive Officer 
New Peer-Reviewed Publication Confirms Unprecedented Response Rates for STRATA's Excimer Laser Combined with JAK Inhibitors in Pediatric Vitiligo 
Short Interest in Strata Skin Sciences, Inc. (NASDAQ:SSKN) Rises By 89.2% 
Hims & Hers Health (NYSE:HIMS) & Strata Skin Sciences (NASDAQ:SSKN) Head-To-Head Analysis 
Critical Comparison: Clover Health Investments (NASDAQ:CLOV) and Strata Skin Sciences (NASDAQ:SSKN) 
STRATA Skin Sciences Confirms Nasdaq Delisting 
12 Health Care Stocks Moving In Wednesday's Intraday Session 
SSKN Stock Falls Despite Meta-Analysis Backs Excimer Laser's Efficacy 
Strata Skin Sciences Partners with Johns Hopkins to Expand Access to Targeted Skin Treatments 
Johns Hopkins Dermatology Expands Advanced Care for Inflammatory and Autoimmune Skin Conditions with Addition of XTRAC® Excimer Laser
Your note
Sign in to keep a note on SSKN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| 22NW, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Aug 15, 2023 | 0 |
| ACCELMED GROWTH PARTNERS, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jul 14, 2024 | 5,767,340 |
| GEIGER URI | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Jul 14, 2024 | 0 |
| GOV SHMUEL | Chief Operating Officer | Purchase | Nov 30, 2023 | 20,000 |
| LESOVITZ CHRISTOPHER | Chief Financial Officer | Purchase | Aug 9, 2023 | 38,282 |
| MOCCIA ROBERT JOSEPH | Chief Executive Officer | Purchase | Aug 9, 2023 | 235,300 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| 22NW, LP | 12.87% | 536,995 | 1.55M | Sep 29, 2024 |
| Nantahala Capital Management, LLC | 9.68% | 403,917 | 1.16M | Sep 29, 2024 |
| Renaissance Technologies, LLC | 2.51% | 104,521 | 301.02K | Sep 29, 2024 |
| Vanguard Group Inc | 2.02% | 84,316 | 242.83K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.52% | 21,852 | 62.93K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.40% | 16,862 | 48.56K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.42% | 59,324 | 170.85K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.56% | 23,545 | 67.81K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.26% | 10,825 | 31.18K | Oct 30, 2024 |
| Perritt Ultra MicroCap Fund | 0.24% | 10,000 | 28.80K | Jul 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.07% | 3,055 | 8.80K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.04% | 1,744 | 5.02K | Oct 30, 2024 |